Report Company Directory
- Alvotech og Teva ná samningi um að sala AVT06 hliðstæðunnar við Eylea má hefjast í Bandaríkjunum á fjórða ársfjórðungi 2026 by GlobeNewsWire
- Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® by GlobeNewsWire
- Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® by GlobeNewsWire
- Mikil umframeftirspurn alþjóðlegra fjárfesta í útboði Alvotech á breytanlegra skuldabréfum að fjárhæð 108 milljónir dollara by GlobeNewsWire
- Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering by GlobeNewsWire
- Alvotech býður út breytanleg skuldabréf að fjárhæð 100 milljónir bandaríkjadala til að viðhalda fjárfestingu í lyfjaþróun, framleiðslu, markaðssetningu og styrkja lausafjárstöðu, staðfestir afkomuspá 2025 og birtir afkomuspá ársins 2026 by GlobeNewsWire
- Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance by GlobeNewsWire
- Markaðsleyfi veitt á Evrópska efnahagssvæðinu fyrir AVT03, hliðstæðu Alvotech við líftæknilyfin Prolia og Xgeva by GlobeNewsWire
- Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area by GlobeNewsWire
- Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area by GlobeNewsWire